<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is one of the most commonly diagnosed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Peroxisome proliferator-activated receptor γ (PPARγ) <z:chebi fb="4" ids="48705">agonists</z:chebi> represent a potentially important family of chemopreventive/therapeutic compounds for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment by affecting cell proliferation, differentiation, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Dual ligands for PPARα and PPARγ, such as netoglitazone (MCC-555), have been developed to improve treatment of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndromes</z:e>, including <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Interestingly, these dual ligands also possess anti-proliferative activities against a variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines with a greater potency than conventional PPARγ specific ligands </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, chemopreventive properties of MCC-555 in colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> were evaluated using azoxymethane (AOM)-induced colonic <z:mpath ids='MPATH_557'>aberrant crypt foci</z:mpath> (ACF) in A/J mice </plain></SENT>
<SENT sid="5" pm="."><plain>We found that MCC-555 suppressed AOM-induced ACF in A/J mice, compared to the control group </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of MCC-555 resulted in decreased mitoses and increased apoptotic cells in the colon </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, expression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor protein MUC2 was increased in MCC-555 treated mice </plain></SENT>
<SENT sid="8" pm="."><plain>Our data clearly suggest that MCC-555 has an effect on the early events of colon <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, thus providing evidence that MCC-555 could be a potential preventive compound for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>